ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although point mutations in the ABL kinase domain appear to be the main cause of secondary resistance to imatinib, such point mutations do not appear to account for all of the resistance observed in patients with the accelerated form of CML [4–8].